title: Sustained clinical resolution of acquired epidermodysplasia verruciformis in an immunocompromised patient after discontinuation of oral acitretin with topical imiquimod.
abstract: Increased cases of acquired epidermodysplasia verruciformis (EDV) have been reported in patients with human immunodeficiency virus (HIV). With regard to management, there are no randomized controlled trials in either immunocompetent or immunocompromised patients, and only a limited number of anecdotal treatment options. Systemic retinoids, either independently or in combination with other treatment modalities, have been used with limited success, demonstrating transient clinical response and recurrence of lesions after cessation of therapy. We report a case of an HIV-positive patient with acquired EDV who achieved sustained clinical resolution even after discontinuation of oral acitretin by applying topical imiquimod to prevent recurrence of his lesions.
authors.affiliation: Department of Dermatology, St Luke’s-Roosevelt Hospital Centers and Beth Israel Medical Center, New York, NY, USA. rajivnijhawan@gmail.com
authors.forename: Rajiv I
authors.initials: RI
authors.lastname: Nijhawan
authors.forename: Achiamah
authors.initials: A
authors.lastname: Osei-Tutu
authors.forename: Jeremy M
authors.initials: JM
authors.lastname: Hugh
mesh_terms: D017255:Acitretin / Q000008:administration & dosage / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D004819:Epidermodysplasia Verruciformis / Q000188:drug therapy* / Q000821:virology; D015658:HIV Infections / Q000150:complications; D006801:Humans; D000077271:Imiquimod; D016867:Immunocompromised Host; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D007641:Keratolytic Agents; D017255:Acitretin; D000077271:Imiquimod